NASDAQ:MGTX MeiraGTx Q4 2024 Earnings Report $5.09 -0.01 (-0.20%) Closing price 04:00 PM EasternExtended Trading$5.01 -0.08 (-1.47%) As of 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast MeiraGTx EPS ResultsActual EPS-$0.50Consensus EPS -$0.48Beat/MissMissed by -$0.02One Year Ago EPSN/AMeiraGTx Revenue ResultsActual Revenue$21.39 millionExpected Revenue$1.50 millionBeat/MissBeat by +$19.89 millionYoY Revenue GrowthN/AMeiraGTx Announcement DetailsQuarterQ4 2024Date3/13/2025TimeBefore Market OpensConference Call DateWednesday, March 12, 2025Conference Call Time7:00PM ETUpcoming EarningsMeiraGTx's Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Tuesday, August 12, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) MeiraGTx Earnings HeadlinesFY2025 EPS Estimates for MeiraGTx Lowered by Chardan CapitalMay 20, 2025 | americanbankingnews.comChardan Capital Lowers MeiraGTx (NASDAQ:MGTX) Price Target to $35.00May 17, 2025 | americanbankingnews.comHow Trade Wars Are Creating Fresh Opportunities for InvestorsTariffs and trade tensions are back in the headlines, and while many are focused on the risks, smart investors know there’s also opportunity. New supply chain shifts, pricing power adjustments, and sector revaluations are already underway—creating openings for those who act early. That’s why we’ve just released our latest research: 📈 “From Tariffs to Returns: How to Capitalize on Trade Disputes in Your Portfolio”May 27, 2025 | Darwin (Ad)MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual MeetingMay 13, 2025 | globenewswire.comMeiraGTx Reports First Quarter 2025 Financial and Operational ResultsMay 13, 2025 | globenewswire.comFDA grants RMAT status to MeiraGTx’s Parkinson’s treatmentMay 11, 2025 | investing.comSee More MeiraGTx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MeiraGTx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MeiraGTx and other key companies, straight to your email. Email Address About MeiraGTxMeiraGTx (NASDAQ:MGTX), a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.View MeiraGTx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBooz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong Earnings Upcoming Earnings NVIDIA (5/28/2025)Synopsys (5/28/2025)Bank of Montreal (5/28/2025)Salesforce (5/28/2025)Haleon (5/28/2025)Costco Wholesale (5/29/2025)Marvell Technology (5/29/2025)Canadian Imperial Bank of Commerce (5/29/2025)Dell Technologies (5/29/2025)National Grid (5/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
